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Indianapolis, Indiana
Ventricular arrhythmia (VA) in structurally normal hearts can be broadly considered under non–life-threatening
monomorphic and life-threatening polymorphic rhythms. Monomorphic VA is classified on the basis of site of
origin in the heart, and the most common areas are the ventricular outflow tracts and left ventricular fascicles.
The morphology of the QRS complexes on electrocardiogram is an excellent tool to identify the site of origin of
the rhythm. Although these arrhythmias are common and generally carry an excellent prognosis, rare sudden
death events have been reported. Very frequent ventricular ectopy may also result in a cardiomyopathy in a mi-
nority of patients. Suppression of VA may be achieved using calcium-channel blockers, beta-adrenergic blockers,
and class I or III antiarrhythmic drugs. Radiofrequency ablation has emerged as an excellent option to eliminate
these arrhythmias, although certain foci including aortic cusps and epicardium may be technically challenging.
Polymorphic ventricular tachycardia (VT) is rare and generally occurs in patients with genetic ion channel disor-
ders including long QT syndrome, Brugada syndrome, catecholaminergic polymorphic VT, and short QT syn-
drome. Unlike monomorphic VT, these arrhythmic syndromes are associated with sudden death. While the car-
diac gross morphology is normal, suggesting a structurally normal heart, abnormalities exist at the
molecular level and predispose them to arrhythmias. Another fascinating area, idiopathic ventricular fibrilla-
tion and early repolarization syndrome, are undergoing research for a genetic basis. (J Am Coll Cardiol
2012;59:1733–44) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2012.01.036Patients with ventricular arrhythmia (VA) require an eval-
uation to determine if structural heart disease is present (1).
In addition to a complete history and physical examination,
all patients should receive a 12-lead electrocardiogram
(ECG), 2-dimensional echocardiogram, and exercise testing
if they have an intermediate or more chance of having
coronary heart disease (1). The ECG can also be useful to
identify various ion channel abnormalities such as long QT
syndrome (LQTS) associated with sudden cardiac death
(SCD) in patients with no structural heart disease (1).
Coronary angiography can be useful to exclude coronary heart
isease in patients with life-threatening VAs such as
olymorphic ventricular tachycardia (PMVT) (1). Car-
diovascular magnetic resonance imaging may be appropri-
ate if echocardiography does not provide an accurate assess-
ment of ventricular function, e.g., in arrhythmogenic right
ventricular cardiomyopathy/dysplasia or sarcoidosis (1–5).
The overwhelming majority of VAs in patients without
structural heart disease carry an excellent prognosis, and
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2011, accepted January 6, 2012.include premature ventricular complexes (PVCs), nonsus-
tained VT, repetitive monomorphic VT, and sustained
monomorphic VT. A small minority of patients may be
prone to life-threatening rapid PMVT and ventricular
fibrillation (VF). These mostly occur with the genetic
arrhythmic syndromes or idiopathic VF (Table 1). This
review will cover the clinical features and management
options for patients without structural heart disease who
have benign and potentially lethal VAs.
Non–Life-Threatening Ventricular Arrhythmias,
Typically Monomorphic
General considerations. The decision to suppress VAs
that are not life-threatening depends on the severity of
patient symptoms, but a potential additional reason may be
to prevent a tachycardia-related cardiomyopathy (TCM)
(6–11). Tachycardia-related cardiomyopathy has occurred
with very frequent runs of VT as well as PVCs, although
why PVCs alone cause it is not clear. The threshold of
ectopy needed to result in TCM has been evaluated by many
authors. Yarlagadda et al. (6) demonstrated in patients with
17,000 ectopic beats daily that successful ablation of
ectopy resulted in improvement of ventricular function.
Takemoto et al. (7) used the cutoff of PVC counts of 20%
total heartbeats over 24 h; Baman et al. (11) had a cut-off
value 24% PVC burden daily; Hasdemir et al. (10) used a
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heartbeats; and Niwano et al. (9)
noted a cut-off of 31,268 PVCs
per 24-h period. Thus, patients
likely need to have 10,000
PVCs per day over a substantial
period to cause TCM. Fortu-
nately, TCM does not appear to
be very common, and occurred in
6.8% of patients in 1 study (10)
and only 13 of 239 patients pre-
senting with frequent PVCs daily
over a 4-year period had a signif-
icant reduction in left ventricular
ejection fraction (9).
Because TCM develops in only
a minority of patients with very
frequent PVCs and nonsustained
VT, it appears reasonable to with-
hold antiarrhythmic therapy in
such patients who have minimal
symptoms and to re-evaluate their
ventricular function on a yearly
basis or sooner if symptoms occur.
Outflow tract VA. Idiopathic
VAs can originate in more than 1
area of the heart but are most
common in the outflow tract area
(Table 1), nearly 80% of which originate from the right
ventricular outflow tract (RVOT) (12). Other common
outflow tract sites include left ventricular outflow tract
(LVOT), the aortic sinuses of Valsalva, the area of aorto-
mitral continuity, the superior basal septum near the His
bundle, the pulmonary artery, and the epicardial surface of
the outflow tracts (13–21).
ANATOMIC CORRELATES. The RVOT is leftward and an-
terior to the LVOT, and the pulmonic valve is superior to
the aortic valve. The RVOT is a muscular infundibulum
circumferentially whereas LVOT is part muscular and part
fibrous. A large of part of right and some part of left aortic
sinuses of Valsalva overlie the muscular LVOT and are in
close proximity to the atrioventricular node and His bundle.
The VAs arising from these areas may show early activation
near the His bundle region. The non-coronary cusp and
posterior aspect of left coronary cusp are continuous with
the fibrous aortomitral continuity, explaining the lack of
VAs related to the non-coronary cusp. The VAs from the
aortic sinuses of Valsalva arise from muscular extensions of
the LVOT to areas above the base of the aortic valve cusps.
These muscle fibers often exhibit slow conduction and
fractionated electrograms. Localization of site of VA origin
can be predicted using the QRS morphology on surface
ECG, and the anatomic relationships help to explain the
shared ECG patterns and subtle differences (Fig. 1) (22).
Abbreviations
and Acronyms
ECG  electrocardiogram
ICD  implantable
cardioverter-defibrillator
IVF  idiopathic ventricular
fibrillation
LQTS  long QT syndrome
LVOT  left ventricular
outflow tract
OTA  outflow tract
arrhythmias
PMVT  polymorphic
ventricular tachycardia
PVC  premature
ventricular complex
RVOT  right ventricular
outflow tract
SCD  sudden cardiac
death
TCM  tachycardia-related
cardiomyopathy
VA  ventricular arrhythmia
VF  ventricular fibrillation
VT  ventricular
tachycardiaThe RVOT VAs present with a distinct ECG pattern of leftbundle branch block and inferior axis (Fig. 2) (23–26). In
general, LVOT VAs manifest an early precordial R-wave
transition (in V2 or V3) because of its more posterior
location compared with the RVOT (Fig. 3).
ELECTROPHYSIOLOGIC MECHANISM. It is well established
that outflow tract arrhythmia (OTA) is due to triggered
activity secondary to cyclic adenosine monophosphate–
mediated delayed after depolarizations (23,24,27,28). In-
creased cyclic adenosine monophosphate due to beta-
adrenergic receptor stimulation, for example, with exertion,
results in release of calcium from the sarcoplasmic reticulum
and delayed afterdepolarizations. Thus, the tachycardia may
terminate with Valsalva maneuvers, adenosine, beta-adrenergic
blockade, or calcium-channel blockers (12,27–29).
CLINICAL FEATURES. Typically, OTA occur between the
ges of 20 and 40 years, and may have a slight female
reponderance (30). Patients may be asymptomatic but
ften present with palpitations, chest pain, dyspnea, pre-
yncope, and even syncope. In general, OTA occur more
requently with exertion or emotional stress, and may have
diurnal variation (31,32). Women may have an increase in
ymptoms related to changes in hormonal status (33). In
eneral, the prognosis of truly idiopathic OTA is benign.
ong-term follow-up studies have provided evidence that
he vast majority of patients do not develop structural heart
isease or SCD (34,35). However, as already noted, a small
ercentage of patients with very frequent VAs may have LV
ysfunction over time, and rare reports have documented
Classification of Ventricular Arrhythmiasin the Absence of Stru tural Hear DiseaseTable 1 Classification of V ntricul r Arrhythmiasin the Absence of Structural Heart Disease
I. Non–life-threatening (typically monomorphic)
A. Outflow tract
Right ventricular outflow
Left ventricular outflow
Aortic sinus of Valsalva
Peri His bundle
B. Idiopathic left ventricular tachycardia
Left posterior fascicle
Left anterior fascicle
High septal fascicle
C. Other
Mitral annulus
Tricuspid annulus
Papillary muscle
Perivascular epicardial
II. Life-threatening (typically polymorphic)
A. Genetic syndromes
Long QT
Brugada
Catecholaminergic polymorphic ventricular tachycardia
Short QTB. Idiopathic ventricular fibrillation
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thought to have “benign” OTA (36–38). Viskin et al. (37)
reported 3 such patients who exhibited a relatively short
coupling interval (mean of 340 ms) of the PVCs. However,
in a larger series, RVOT PVCs initiating VF or PMVT had
a mean PVC coupling interval of 409  62 ms, clearly not
short” (36). These characteristics also seem to differ from
he idiopathic VF patients reported by Haissaguerre et al.
39), who had very short-coupled (297  41 ms) PVCs of
Purkinje fiber origin. Unfortunately, there does not seem to
Figure 1 Correlation of Ventricular Ectopy
Site of Origin With ECG Morphology
Correlation of the site of origin of ventricular ectopy with the electrocardiogram
(ECG) morphology in V1. The anatomy of the outflow tract region is such that
areas on the right and left sides of the heart can be in close proximity to each
other. This can give similar ECG patterns in several leads. However, note that
in V1, there is a gradual increase in the amplitude of the r-wave as the site of
origin of the ventricular ectopy moves leftward. Ao  aorta; LA  left atrium;
LV  left ventricle; RVOT  right ventricular outflow tract. Reproduced with per-
mission from Asirvatham et al. (22).
Figure 2 12-Lead ECG of RVOT Ventricular Tachycardia
On this 12-lead electrocardiogram (ECG) of right ventricular outflow tract (RVOT) ve
cordial leads with transition from a small r-wave to a large R-wave at V3 to V4, con
ECG axis.be a specific PVC coupling interval that predicts risk for a
malignant VA.
TREATMENT. Patients presenting in sustained VT may
respond acutely to carotid sinus massage, Valsalva maneu-
vers, or intravenous adenosine or verapamil (40,41). Patients
with no or minimal symptoms may be given reassurance
without specific drug therapy. Long-term oral therapy with
either beta-adrenergic blockers or calcium-channel blockers
may control arrhythmias (40,42,43). Patients nonresponsive
to beta-blockers and calcium-channel blockers may respond
to class I or III antiarrhythmic agents (25,44). Radiofre-
quency catheter ablation may be considered in cases where
medical therapy is ineffective or not tolerated. Multiple reports
have shown excellent outcomes for ablation of OTAs by
discrete radiofrequency lesions (7,13,14,16–20,45,46). Abla-
tion of epicardial or aortic sinuses of Valsalva sites is also highly
effective, but can be technically challenging and carries higher
risks due to these sites’ proximity to coronary arteries.
Idiopathic left VT. Verapamil-sensitive idiopathic left
ventricular tachycardias occur primarily due to re-entry
involving the fascicles of the left bundle branch. Three
varieties may occur: 1) left posterior fascicular VT with a
right bundle branch block and left axis deviation on
ECG; 2) left anterior fascicular VT with a right bundle
branch block and right axis deviation; and 3) high septal
fascicular VT with relatively narrow QRS complex and
normal axis. Left posterior fascicular VT is the most
common form (47–50) (Fig. 4). Patients are young, 15 to
40 years of age, and predominately men (60%). It is
usually paroxysmal, but incessant forms leading to a
TCM have been described (51). In 1981, Belhassen et al.
(52) observed that intravenous verapamil significantly
slowed and often terminated this arrhythmia. In contrast
ar tachycardia, note that there is a left bundle branch block pattern in the pre-
t with a right-sided site of origin. Also consistent with the OT site is the inferiorntricul
sisten
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this tachycardia.
ELECTROPHYSIOLOGIC MECHANISM. Studies based on en-
trainment maneuvers have conclusively demonstrated a
re-entrant mechanism (53–56). The re-entrant circuit is
constituted by an orthodromic limb consisting of a zone of
slow, decremental conduction in the intraventricular left
septum proceeding from the base to the apex (55,56). The
Figure 3 12-Lead ECG of PVCs
A 12-lead electrocardiogram (ECG) of premature ventricular contractions (PVCs) or
morphology in the limb leads is nearly the same as in the example in Figure 2. Ho
r-wave in V1 and V2, and the transition from small to large R-wave is from V2 to V3
intracardiac mapping and ablation confirmed a left ASV site.
Figure 4 12-Lead ECG of Idiopathic Left Ventricular Tachycardi
On this 12-lead electrocardiogram (ECG), note that there is a right bundle branch
This type of tachycardia has a site of origin near the left posterior fascicle.lower turnaround point is toward the apex, and the retro-
grade limb is formed by the Purkinje network.
TREATMENT. Intravenous verapamil slows and terminates the
tachycardia by prolonging conduction in the decremental limb
of the circuit (57,58). Several studies have also demonstrated
long-term effectiveness of oral verapamil (59–61). As in the
case of OTA, beta-blockers, and class I and III antiarrhythmic
agents may be useful in some cases. Catheter ablation is an
g in the left coronary cusp/aortic sinus of Valsalva (ASV). Note that the QRS
, the precordial ECG leads are markedly different. There is a broad but small
ugh that could still be from the right side, a left-sided site is more likely, and
attern with a superior axis.iginatin
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ineffective (Fig. 5) (57,60,62–64 ). The most common ap-
proach during radiofrequency ablation involves the identifica-
tion of the diastolic Purkinje potential during VT (62). In cases
where VT is noninducible, ablation during sinus rhythm using
electroanatomic mapping may be considered (64).
Mitral annulus, tricuspid annulus, papillary muscle,
perivascular epicardial ectopy. Although OTA and fascic-
ular VT form the vast majority of VA in patients with
structurally normal hearts, ectopy may originate from any
myocardial location. Certain sites such as the mitral annulus
(65,66), tricuspid annulus (67), papillary muscles (68,69), and
perivenous epicardial sites (70) show predilection. The ECG of
the ventricular complexes originating from mitral annulus may
show significant slurring of QRS complex onset resembling a
delta-wave morphology seen in patients with ventricular pre-
excitation (65,66). Epicardial foci of VAs are also characterized
by a slurred QRS onset giving a pseudo-delta-wave appearance
(Fig. 6). The slowed initial QRS activation was quantified by
Daniels et al. (70), and a delayed precordial maximum deflec-
tion index 0.55 identified epicardial VTs with high specific-
ty and sensitivity. The VAs from epicardial foci cluster along
he major epicardial vasculature and show catecholamine and
denosine sensitivity.
ife-Threatening Ventricular Arrhythmias,
ypically Polymorphic
enetic syndromes with PMVT. Long QT syndrome,
Figure 5 RF Catheter Ablation of Idiopathic Left VT
Radiofrequency (RF) catheter ablation of idiopathic left ventricular tachycardia (VT)
diac tracings from the ablation catheter near the left ventricle (LV) posterior fascic
Note that at 9 s after onset of 0.3 AMP, the tachycardia terminates. After this ablcatecholaminergic PMVT, Brugada syndrome, and short aQT syndrome are genetic syndromes that predispose to VAs
and SCD (1), especially in young persons. Cardiac gross
morphology and histology are normal, but abnormalities of
ion channels or their regulatory proteins create an arrhyth-
mogenic milieu. These conditions are rare, and taken
together, have an estimated prevalence 5 in 10,000 (1).
espite the diverse nature of these disorders, certain gen-
ralizations can be made. They may be inherited with
ncomplete penetrance and family history does not help to
tratify risk of sudden death. The severity of ECG pheno-
ype, presence of symptoms, and certain genotypes may
redict increased risk. While implantable cardioverter-
efibrillator (ICD) insertion is recommended for secondary
revention of cardiac arrest, primary prevention should be
uided by risk stratification schemes and availability of
ffective medical treatment for a particular syndrome or
enotype.
ong QT syndrome. The LQTS is characterized by ab-
ormally prolonged QT intervals (corrected QT interval
440 ms in men and 460 ms in women) (71) with or
ithout morphological abnormalities of the T waves
Fig. 7). A decrease in outward potassium currents or an
ncrease in inward sodium currents prolongs the repolariza-
ion phase of the cardiac action potential, resulting in
rolongation of the QT interval and predisposition to early
fterdepolarizations and torsade de pointes VT. Twelve
ifferent genes involved in inherited LQTS have been
escribed (72). The first 3—LQT1, LQT2, and LQT3—
ltaneous tracings are electrocardiogram leads I, II, III, aVF, V1, and V6; intracar-
) and at the right ventricle (RV) apex; and the energy delivery tracing (Current).
the VT was no longer inducible.: simu
le (Abl
ation,ccount for 90% of the genotyped LQTS cases (73).
1738 Prystowsky et al. JACC Vol. 59, No. 20, 2012
Ventricular Arrhythmias in Normal Hearts May 15, 2012:1733–44LQT1 and LQT2 are caused by mutations of KCNQ1 and
KCNH2 genes that encode  subunits of IKs and IKr
potassium channels, respectively; LQT3 results from muta-
tions of SCN5A gene that encode  subunits of INa sodium
channels. The remainder involve mutations related to other
channel subunits or their regulator proteins. Approximately
25% of affected patients may not have identifiable gene
mutations (74,75).
The mean age of symptom onset is 12 years, and patients
may present with syncope, seizures, or cardiac arrest. Clin-
ical presentation and ECG repolarization (ST-T) patterns
have been correlated to the genotype (76,77). Patients who
have LQT1 often have broad-based T waves and frequently
experience events during physical activity (especially swim-
Figure 7 12-Lead ECG of LQTS
On this 12-lead electrocardiogram (ECG) of long QT syndrome (LQTS), the QT inter
Genetic testing revealed a LQT1 syndrome.
Figure 6 12-Lead ECG of PVCs Originating From LV Epicardium
On this 12-lead electrocardiogram (ECG) of premature ventricular contractions (PVC
complexes show right bundle branch block morphology in V1 and upright R waves
ance of the QRS complexes in the precordial leads that has been described with s
was confirmed at mapping and ablation.ming). In LQT2, the T-wave is often notched in multiple
leads. Triggers for LQT2 include startling auditory stimuli
(e.g., from an alarm clock) and emotional upset. Patients
who have LQT3 often demonstrate long ST segments.
Most LQT3 events occur at rest or sleep. However, there is
considerable overlap between LQTS genotype, the T-wave
morphology, and the clinical presentation. The diagnosis of
LQTS can be difficult, and the modified Schwartz score
determines the clinical probability for having the condition
on the basis of multiple data points including personal and
family history, QT interval, and T-wave morphology (71).
More recently, diagnostic evaluations such as response to
exercise, epinephrine challenge, and genetic testing have
also been utilized.
80 ms and the corrected QT interval is 513 ms.
nterior Base
ginating from the left ventricular (LV) epicardium at the anterior base, the QRS
leads II, III, and aVF (inferior axis). Key is the broad, pseudodelta-wave appear-
f origin on the mitral annulus and the ventricular epicardium. The site of originval is 5at A
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sures include avoidance of the trigger events and medica-
tions, including over-the-counter pills, that may further
prolong QT interval. Risk stratification schemes based on
the degree of QT prolongation, genotype, and sex have been
developed (78). A corrected QT interval exceeding 500 ms
poses a high risk for cardiac events. Patients who have
LQT2 and LQT3 may be at higher risk for SCD compared
with patients who have LQT1. Beta-blockers are indicated
for all patients with syncope and for asymptomatic patients
with significant QT prolongation (1). The role of beta-
blockers in asymptomatic patients with normal or mildly
prolonged QT intervals remains uncertain. Beta-blockers
are highly effective in LQT1, but less effective in other
LQTS (79,80). The role of beta-blockers in LQT3 is not
established. Because LQT3 is a minority of all LQTS,
symptomatic patients who have not undergone genotyp-
ing should receive beta-blocker therapy. Implantable
cardioverter-defibrillators are indicated for secondary pre-
vention of cardiac arrest and for patients with recurrent
syncope despite beta-blocker therapy (1). Less defined
therapies include gene-specific therapy with mexiletine (81),
flecainide (82), or ranolazine (83) for some LQT3 patients,
permanent pacing for bradycardia-dependent torsade de
pointes, and surgical left cardiac sympathetic denervation
for recurrent arrhythmias resistant to beta-blocker therapy
(1,84). Catheter ablation of triggering PVCs has been
reported to be successful in abolishing recurrent VT/VF in
a few patients (85).
Brugada syndrome. The Brugada syndrome is character-
ized by coving ST-segment elevation in precordial leads V1
to V3 (2 mm in 2 of these 3 leads are diagnostic), complete
r incomplete right bundle branch block pattern, and
linical presentation with syncope or cardiac arrest (Fig. 8)
86,87). This pattern can be spontaneously present or
rovoked by sodium-channel–blocking agents such as aj-
Figure 8 12-Lead ECG of Brugada Syndrome
On this 12-lead electrocardiogram (ECG) of Brugada syndrome, note the coving ofaline, flecainide, or procainamide (87). The syndrome
anifests predominantly in men in the third and fourth
ecades of life. The typical ECG pattern can be transient
nd may only be detected during long-term ECG monitor-
ng. Brugada syndrome has also been linked to SCD in
oung men in Southeast Asia and has several local names,
ncluding Lai Tai (“died during sleep”) in Thailand (88).
atients with Brugada syndrome are also prone to atrial
brillation and sinus node dysfunction. Although 7 different
enes involved in Brugada syndrome have been described,
CN5A gene mutations (BrS1) that lead to a loss of
unction of cardiac sodium channel (NaV 1.5) account for
he vast majority of genotyped cases. However, even in
atients with the typical Brugada syndrome ECG pattern, a
ositive genotype is obtained only a minority (13%) (89).
rS1 and LQT3 share SCN5A mutations as their basis, and
verlapping phenotypes of Brugada syndrome and LQT3
ave been reported (90,91).
There is no well-validated preventive medical therapy for
rugada syndrome, although quinidine has been proposed
o play a role (92). Implantable cardioverter-defibrillators
re effective in preventing sudden death and are indicated
or cardiac arrest survivors (87). The major management
ilemma arises in the decision to place prophylactically an
CD in a Brugada syndrome patient, based on the patient’s
erceived risk of SCD. Patients with Brugada syndrome
ho have not had a cardiac arrest may be risk stratified on
he basis of spontaneous ECG pattern and syncope (93).
atients with spontaneous ECG pattern and syncope are at
igh risk, and ICD insertion is generally recommended for
rimary prophylaxis (86,87). Asymptomatic patients with-
ut spontaneous ECG pattern are at low risk and may be
ollowed up clinically. Asymptomatic patients with sponta-
eous ECG pattern are at intermediate risk, and their best
herapeutic options may need to be individualized. Family
istory of SCD and specific genotypes do not predict events
-segment in the early precordial leads and right bundle branch block pattern.the ST
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inconsistent predictive value (94,95). Fragmented QRS
interval has been reported to predict poor prognosis (96).
Although no preventive medical therapy is available, low-
dose quinidine may be used to treat frequent VAs in
Brugada syndrome patients who already have an ICD (97),
and quinidine and isoproterenol may be useful in patients
having VT storms (98,99). Catheter ablation of triggering
PVCs (85) and ablation of the RV outflow epicardial
musculature (100) have been reported to be successful in
abolishing recurrent VT/VF in a small number of patients.
Catecholaminergic PMVT. Catecholaminergic PMVT is
a disorder of myocardial calcium homeostasis, clinically
manifested as exertional syncope and SCD due to exercise-
induced VT that is often polymorphic or bidirectional
(Fig. 9). The genetic basis is autosomal dominant, although
autosomal recessive forms have been described more re-
cently (101,102). The autosomal dominant form involves
mutation of cardiac ryanodine receptor (RyR2 gene) in
approximately 50% of patients (101,103). The autosomal
recessive form, accounting for only 3% to 5% of genotyped
cases, is due to mutations of the calsequestrin 2 gene
(CASQ2). The ryanodine receptor spans the membrane of
the sarcoplasmic reticulum and releases calcium triggered by
calcium entry into the cell through L-type calcium channels.
Calsequestrin is a protein that sequestrates calcium ions
within the sarcoplasmic reticulum. Both RyR2 and CASQ2
mutations cause intracellular calcium overload and delayed
afterdepolarizations that form the basis of arrhythmogenesis
in catecholaminergic PMVT.
The resting ECG is unremarkable, but the typical VT
patterns are reproducible with exercise or catecholamine
Figure 9 ECG Rhythm Strips of Child With CPVT
The electrocardiogram (ECG) rhythm strips of a 6-year-old girl with catecholaminerg
seizures with physical activity and was brought to the Emergency Department afte
degenerated to ventricular fibrillation (bottom panel). Genetic testing uncovered ainfusion. The VAs typically appear during sinus tachycardia drates of 120 beats/min to 130 beats/min, with progressive
frequency of PVCs followed by bursts of polymorphic or
bidirectional VT (104). The mean age for presentation with
syncope is 7.8  4 years (104). Electrophysiology study is
ot helpful in risk stratification. The mainstay of medical
anagement is beta-blocker therapy, although as many as
6% may have recurrent events while receiving therapy
103,105). Calcium-channel blockers (106) may have lim-
ted effectiveness as adjunctive therapy. Flecainide blocks
he RyR2 receptor and shows promise as a medical therapy,
lthough prospective data are lacking (107,108). Because of
he limitations of medical therapy, ICD insertion is appro-
riate for many patients who have had a cardiac arrest and
or patients with life-threatening VA despite maximal
edical therapy. Recurrent ICD shocks may occur, and an
nitial shock with its accompanying pain and anxiety may
rigger further VAs. Surgical left cardiac sympathetic de-
ervation may be used in resistant cases (109).
hort QT syndrome. Short QT syndrome is a rare disor-
er characterized by abnormally short QT intervals of300
o 320 ms. The exact cutoff QT intervals for diagnosis are
till debated, and diagnostic criteria involving corrected QT
nterval, clinical history, and genotyping have been proposed
110). The syndrome is associated with SCD and atrial
brillation, and patients may present early in childhood.
utations leading to gain of function of 3 genes encoding
or repolarizing potassium currents (IKr, IKs, and IK1) have
een associated with short QT syndrome. Only limited
linical experience has been reported, and the disease may be
ssociated with a high incidence of SCD, leading many to
ecommend ICD implantation for secondary and primary
revention (111). Preliminary observations suggest quini-
morphic ventricular tachycardia (CPVT) are shown. The patient had a history of
an episode, when the tracing was recorded. Bidirectional VT (upper panel)
ine-2 receptor defect. Figure provided by Len Steinberg, MD.ic poly
r such
ryanidine might be useful (112).
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Idiopathic ventricular fibrillation (IVF) presents as syncope
or SCD in young people with normal hearts and no
identifiable genetic syndrome. The events are typically
unrelated to stress or activity, but may occur in clusters
characterized by frequent ventricular ectopy and short epi-
sodes of VF or PMVT. The spontaneous VF or PMVT
events are triggered by PVCs, generally with a short
coupling interval, often referred to as “short coupled tor-
sade.” The PVCs triggering the events may arise from the
Purkinje fibers or the myocardium, and the former generally
has shorter coupling intervals (see section, Outflow tract
VA). Isoproterenol may be effective in suppressing VF
storms in the acute setting, and quinidine may be useful on
a long-term basis (113). Insertion of an ICD is recom-
mended for all cases of IVF.
Haissaguerre et al. (39) described 27 patients who were
resuscitated from recurrent IVF. Of the 24 patients with
frequent PVCs, electrophysiologic mapping identified the
PVCs originating from the RVOT in 4 patients and from
the distal Purkinje system right ventricle or left ventricle in
20 patients. Catheter ablation eliminated the PVCs in all
patients, and during a mean follow-up of 24  28 months,
there was no recurrent VF in 24 of the 27 patients.
Long-term follow-up of such patients (mean 63 months)
also indicates excellent results from ablation of the trigger-
ing PVCs (114).
Early repolarization pattern, defined as elevated QRS-ST
junction (J point) of at least 0.1 mV from baseline in the
inferior or lateral ECG leads occurs more frequently in
patients with IVF than in normal subjects (31% vs. 5%)
(115). Such a pattern in the anterior precordial leads (V1 to
V3) was excluded from the studies as it could occur in
disease states such as Brugada syndrome and arrhythmo-
genic right ventricular cardiomyopathy/dysplasia. Further,
early repolarization pattern in the anterior precordial leads is
considered to have a benign prognosis (116). Recent data
suggest the KCNJ8 gene may be involved in early repolar-
ization syndrome (117). Early repolarization pattern is not
uncommon and has for years been considered a normal
ECG variant with a benign prognosis (116). The mecha-
nism of VT or VF that can occur with it is not well
understood (116). A recent study suggests the early repo-
larization with the ST segment showing a horizontal/
descending pattern, but not the one with the ascending
pattern, is associated with an increased risk for arrhythmic
death (118). Still, the overall risk of SCD is very small. Until
more is known about how to risk-stratify patients with the
early repolarization syndrome, no specific work-up or ther-
apy is recommended.
Conclusions
Ventricular arrhythmias in structurally normal hearts are
typically monomorphic with a benign prognosis. The usualwork-up to rule out structural heart disease includes an
ECG and echocardiogram, but some patients may require
cardiovascular magnetic resonance imaging or cardiac cath-
eterization. If symptoms are mild, no therapy is usually
necessary, but drugs—for example, beta-blockers or vera-
pamil—or radiofrequency catheter ablation may be used for
symptomatic patients. The genetic ion channelopathies and
idiopathic VF present with PMVT that is potentially
life-threatening. Such patients may require ICD therapy for
secondary or primary prevention of SCD.
Reprint requests and correspondence: Dr. Eric N. Prystowsky,
The St. Vincent Medical Group, 8333 Naab Road, Indianapolis,
Indiana 46260. E-mail: eprystow@thecaregroup.com.
REFERENCES
1. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006
guidelines for management of patients with ventricular arrhythmias
and the prevention of sudden cardiac death: a report of the American
College of Cardiology/American Heart Association Task Force and
the European Society of Cardiology Committee for Practice Guide-
lines (Writing Committee to Develop Guidelines for Management of
Patients With Ventricular Arrhythmias and the Prevention of Sud-
den Cardiac Death). J Am Coll Cardiol 2006;48:e247–346.
2. Kies P, Bootsma M, Bax J, et al. Serial reevaluation for ARVD/C is
indicated in patients presenting with left bundle branch block
ventricular tachycardia and minor ECG abnormalities. J Cardiovasc
Electrophysiol 2006;17:586–93.
3. Ladyjanskaia GA, Basso C, Hobbelink MGG, et al. Sarcoid myo-
carditis with ventricular tachycardia mimicking ARVD/C. J Cardio-
vasc Electrophysiol 2010;21:94–8.
4. Kim JS, Judson MA, Donnino R, et al. Cardiac sarcoidosis. Am
Heart J 2009;157:9–21.
5. Hoffmayer KS, Machado ON, Marcus GM, et al. Electrocardio-
graphic comparison of ventricular arrhythmias in patients with
arrhythmogenic right ventricular cardiomyopathy and right ventric-
ular outflow tract tachycardia. J Am Coll Cardiol 2011;58:831–8.
6. Yarlagadda RK, Iwai S, Stein KM, et al. Reversal of cardiomyopathy
in patients with repetitive monomorphic ventricular ectopy originat-
ing from the right ventricular outflow tract. Circulation 2005;112:
1092–7.
7. Takemoto M, Yoshimura H, Ohba Y, et al. Radiofrequency catheter
ablation of premature ventricular complexes from right ventricular
outflow tract improves left ventricular dilation and clinical status in
patients without structural heart disease. J Am Coll Cardiol 2005;45:
1259–65.
8. Sekiguchi Y, Aonuma K, Yamauchi Y, et al. Chronic hemodynamic
effects after radiofrequency catheter ablation of frequent monomor-
phic ventricular premature beats. J Cardiovasc Electrophysiol 2005;
16:1057–63.
9. Niwano S, Wakisaka Y, Niwano H, et al. Prognostic significance of
frequent premature ventricular contractions originating from the
ventricular outflow tract in patients with normal left ventricular
function. Heart 2009;95:1230–7.
10. Hasdemir C, Ulucan C, Yavuzgil O, et al. Tachycardia-induced
cardiomyopathy in patients with idiopathic ventricular arrhythmias:
the incidence, clinical and electrophysiologic characteristics, and the
predictors. J Cardiovasc Electrophysiol 2011;22:663–8.
11. Baman TS, Lange DC, Ilg KJ, et al. Relationship between burden of
premature ventricular complexes and left ventricular function. Heart
Rhythm 2010;7:865–9.
12. Kim RJ, Iwai S, Markowitz SM, Shah BK, Stein KM, Lerman BB.
Clinical and electrophysiological spectrum of idiopathic ventricular
outflow tract arrhythmias. J Am Coll Cardiol 2007;49:2035–43.
13. Joshi S, Wilber D. Ablation of idiopathic right ventricular outflow
tract tachycardia: current perspectives. J Cardiovasc Electrophysiol
2005;16 Suppl 1:52–8.
1742 Prystowsky et al. JACC Vol. 59, No. 20, 2012
Ventricular Arrhythmias in Normal Hearts May 15, 2012:1733–4414. Dixit S, Lin D, Marchlinski FE. Ablation of ventricular outflow tract
tachycardias. In: Huang SKS, Wood MA, editors. Catheter Ablation
of Cardiac Arrhythmias. Philadelphia, PA: Saunders Elsevier, 2006:
473–90.
15. Sekiguchi Y, Aonuma K, Takahashi A, et al. Electrocardiographic
and electrophysiologic characteristics of ventricular tachycardia orig-
inating within the pulmonary artery. J Am Coll Cardiol 2005:45:
887–95.
16. Yamauchi Y, Aonuma K, Takahashi A, et al. Electrocardiographic
characteristics of repetitive monomorphic right ventricular tachycar-
dia originating near the his-bundle. J Cardiovasc Electrophysiol
2005;16:1041–8.
17. Kanagaratnam L, Tomassoni G, Schweikert R, et al. Ventricular
tachycardias arising from the aortic sinus of Valsalva: an under-
recognized variant of left outflow tract ventricular tachycardia. J Am
Coll Cardiol 2001;37:1408–11.
18. Yamada T, McElderry HT, Okada T, et al. Idiopathic left ventricular
arrhythmias originating adjacent to the left aortic sinus of Valsava:
electrophysiological rationale for the surface electrocardiogram.
J Cardiovasc Electrophysiol 2010;21:170–6.
19. Alasady M, Singleton CB, McGavigan, AD. Left ventricular outflow
tract ventricular tachycardia originating from the noncoronary cusp:
electrocardiographic and electrophysiological characterization and radio-
frequency ablation. J Cardiovasc Electrophysiol 2009;20:1287–90.
20. Kumagai K, Fukuda K, Wakayama Y, et al. Electrocardiographic
characteristics of the variants of idiopathic left ventricular outflow
tract ventricular tachyarrhythmias. J Cardiovasc Electrophysiol 2008;
19:495–501.
21. Tada H, Nogami A, Naito S, et al. Left ventricular epicardial outflow
tract tachycardia—a new distinct subgroup of outflow tract tachycar-
dia. Jpn Circ J 2001;65:723–30.
22. Asirvatham SJ. Correlative anatomy for the invasive electrophysiolo-
gist: outflow tract and supravalvar arrhythmia. J Cardiovasc Electro-
physiol 2009;20:955–68.
23. Iwai S, Cantillon DJ, Kim RJ, et al. Right and left ventricular outflow
tract tachycardias: evidence for a common electrophysiologic mech-
anism. J Cardiovasc Electrophysiol 2006;17:1052–8.
24. Yamawake N, Nishizaki M, Hayashi T, et al. Autonomic and
pharmacological responses of idiopathic ventricular tachycardia aris-
ing from the left ventricular outflow tract. J Cardiovasc Electro-
physiol 2007;18:1161–6.
25. Brooks F, Burgess H. Idiopathic ventricular tachycardia. Medicine
1988:67:271–94.
26. Lerman BB, Stein KM, Markowitz SM. Mechanisms of idiopathic left
ventricular tachycardia. J Cardiovasc Electrophysiol 1997;8:571–83.
27. Lerman BB, Stein KM, Markowitz SM. Adenosine sensitive ven-
tricular tachycardia: a conceptual approach. J Cardiovasc Electro-
physiol 1996;7:559–69.
28. Lerman BB. Response of nonreentrant catecholamine-mediated
ventricular tachycardia to endogenous adenosine and acetylcholine.
Circulation 1993;87:382–90.
29. Wilber DJ, Baerman J, Olshansky B, et al. Adenosine-sensitive
ventricular tachycardia: clinical characteristics and response to cath-
eter ablation. Circulation 1993;87:126–34.
30. Nakagawa M, Takahashi N, Nobe S, et al. Gender differences in
various types of idiopathic ventricular tachycardia. J Cardiovasc
Electrophysiol 2002;13:633–8.
31. Gill JS, Prasad K, Blaszyk K, et al. Initiating sequences in exercise
induced idiopathic ventricular tachycardia of left bundle branch-like
morphology. Pacing Clin Electrophysiol 1998;21:1873–80.
32. Hayashi H, Fujiki A, Tani M, et al. Circadian variation of idiopathic
ventricular tachycardia originating from right ventricular outflow
tract. Am J Cardiol 1999;84:99–101.
33. Marchlinski FE, Deely MP, Zado ES. Sex-specific triggers for right
ventricular outflow tract tachycardia. Am Heart J 2000;139:1009–13.
34. Lemery R, Brugada P, Bella PD, et al. Nonischemic ventricular
tachycardia: clinical course and long-term follow-up in patients
without clinically overt heart disease. Circulation 1989;79:990–9.
35. Goy JJ, Tauxe F, Fromer M, et al. Ten-years follow-up of 20 patients
with idiopathic ventricular tachycardia. Pacing Clin Electrophysiol
1990;13:1142–7.
36. Noda T, Shimizu W, Taguchi A, et al. Malignant entity of idiopathic
ventricular fibrillation and polymorphic ventricular tachycardia initi-ated by premature extrasystoles originating from the right ventricular
outflow tract. J Am Coll Cardiol 2005;46:1288–94.
37. Viskin S, Rosso R, Rogowski O, Belahssen B. The “short-coupled”
variant of right ventricular outflow ventricular tachycardia: a not-so-
benign ventricular tachycardia? J Cardiovasc Electrophysiol 2005;16:
912–6.
38. Botoni N, Quartieri F, Lolli G, Lori M, Manari N, Menozzi C.
Sudden death in a patient with idiopathic right ventricular outflow
tract arrhythmia. J Cardiovasc Med 2009;10:801–3.
39. Haissaguerre M, Shoda M, Jais P, et al. Mapping and ablation of
idiopathic ventricular fibrillation. Circulation 2002;106:962–7.
40. Lerman B. Ventricular tachycardia in patients with structurally
normal hearts. In: Zipes DP, Jalife J, editors. Cardiac Electrophysi-
ology: From Cell to Bedside. 5th ed. Philadelphia, PA: WB Saun-
ders, 2009:657–67.
41. Buxton AE, Marchlinski FE, Doherty JU, et al. Repetitive, mono-
morphic ventricular tachycardia: clinical and electrophysiologic char-
acteristics in patients with and patients without organic heart disease.
Am J Cardiol 1984;54:997–1002.
42. Krittayaphong R, Bhuripanyo K, Punlee K, Kangkagate C, Chaithi-
raphan S. Effect of atenolol on symptomatic ventricular arrhythmia
without structural heart disease: a randomized placebo-controlled
study. Am Heart J 2002;144:e15.
43. Gill JS, Blaszyk K, Ward DE, et al. Verapamil for suppression of
idiopathic ventricular tachycardia of left bundle branch-like morphol-
ogy. Am Heart J 1993;126:1126–33.
44. Rahilly GT, Prystowsky EN, Zipes DP, et al. Clinical and electro-
physiologic findings in patients with repetitive monomorphic ven-
tricular tachycardia and otherwise normal electrocardiogram. Am J
Cardiol 1982;50:459–68.
45. Callans DJ. Catheter ablation of idiopathic ventricular tachycardia
arising from the aortic root. J Cardiovasc Electrophysiol 2009;20:
969–72.
46. Yamashina Y, Yagi T, Namekawa A, et al. Clinical and electrophys-
iological difference between idiopathic right ventricular outflow tract
arrhythmias and pulmonary artery arrhythmias. J Cardiovasc Elec-
trophysiol 2010;21:163–9.
47. Ward DE, Nathan AW, Camm AJ. Fascicular tachycardia sensitive
to calcium antagonists. Eur Heart J 1984;5:896–905.
48. Lin FC, Finley D, Rahimtoola SH, Wu D. Idiopathic paroxysmal
ventricular tachycardia with a QRS pattern of right bundle branch
block and left axis deviation: a unique clinical entity with specific
properties. Am J Cardiol 1983;52:95–100.
49. Nogami A, Naito S, Tada H, et al. Verapamil-sensitive left anterior
fascicular ventricular tachycardia: results of radiofrequency ablation in
six patients. J Cardiovasc Electrophysiol 1998;9:1269–78.
50. Nogami A. Idiopathic left ventricular tachycardia: assessment and
treatment. Card Electrophysiol Rev 2002;8:448–57.
51. Toivonen L, Nieminen M. Persistent ventricular tachycardia result-
ing in left ventricular dilatation treated with verapamil. Int J Cardiol
1986;13:361–5.
52. Belhassen B, Rotmensch HH, Laniado S. Response of recurrent
sustained ventricular tachycardia to verapamil. Br Heart J 1981;46:
679–82.
53. Okumura K, Matsuyama K, Miyagi H, et al. Entrainment of
idiopathic ventricular tachycardia of left ventricular origin with
evidence for reentry with an area of slow conduction and effect of
verapamil. Am J Cardiol 1988;62:727–32.
54. Maruyama M, Tadera T, Miyamoto S, Ino T. Demonstration of the
reentrant circuit of verapamil sensitive idiopathic left ventricular
tachycardia: direct evidence for macroreentry as the underlying
mechanism. J Cardiovasc Electrophysiol 2001;12:968–72.
55. Aiba T, Suyama K, Aihara N, et al. The role of the Purkinje and
pre-Purkinje potentials in the reentrant circuit of verapamil sensitive
idiopathic LV tachycardia. Pacing Clin Electrophysiol 2001;24:333–44.
56. Ramprakash B, Jaishankar S, Hygriv BR, et al. Catheter ablation of
fascicular ventricular tachycardia. Indian Pac Electrophysiol J 2008;
8:193–201.
57. Nogami A, Naito S, Tada H, et al. Demonstration of diastolic and
pre-systolic Purkinje potentials as critical potentials in a macroreentry
circuit of verapamil-sensitive idiopathic left ventricular tachycardia.
J Am Coll Cardiol 2000;36:811–23.
58. Nogami A. Diagnosis and ablation of fascicular tachycardia. Eur
Cardiol 2010;6:79–85.
1743JACC Vol. 59, No. 20, 2012 Prystowsky et al.
May 15, 2012:1733–44 Ventricular Arrhythmias in Normal Hearts59. German LD, Packer DL, Bardy, Gallagher JJ. Ventricular tachycar-
dia induced by atrial stimulation in patients without symptomatic
cardiac disease. Am J Cardiol 1983;52:1202–7.
60. Ohe T, Aihara N, Kamakura S, et al. Long-term outcome of
verapamil-sensitive sustained left ventricular tachycardia in patients
without structural heart disease. J Am Coll Cardiol 1995;25:54–8.
61. Klein GJ, Millman PJ, Yee R. Recurrent ventricular tachycardia
responsive to verapamil. PACE 1984;7:938–48.
62. Nakagawa H, Beckman KJ, McClelland JH, et al. Radiofrequency
catheter ablation of idiopathic left ventricular tachycardia guided by a
Purkinje potential. Circulation 1993;88:2607–17.
63. Tsuchiya T, Okumura K, Honda T, et al. Significance of late
diastolic potential preceding Purkinje potential in verapamil-sensitive
idiopathic left ventricular tachycardia. Circulation 1999;99:2408–13.
64. Lin D, Hsia HH, Gerstenfeld EP, et al. Idiopathic fascicular
tachycardia: linear ablation lesion strategy for noninducible or non-
sustained tachycardia. Heart Rhythm 2005;2:934–9.
65. Tada H, Ito S, Naito S, Kurosaki K, et al. Idiopathic ventricular
arrhythmia arising from the mitral annulus: a distinct subgroup of
idiopathic ventricular arrhythmias. J Am Coll Cardiol 2005;45:877–86.
66. Kumagai K, Yamauchi Y, Takahashi A, et al. Idiopathic left
ventricular tachycardia originating from the mitral annulus. J Car-
diovasc Electrophysiol 2005;16:1029–36.
67. Tada H, Tadokoro K, Ito S, et al. Idiopathic ventricular arrhythmias
originating from the tricuspid annulus: prevalence, electrocardio-
graphic characteristics, and results of radiofrequency catheter abla-
tion. Heart Rhythm 2007;4:7–16.
68. Doppalapudi H, Yamada T, McElderry T, Plumb V, Epstein AE,
Kay GN. Ventricular tachycardia originating from the posterior
papillary muscle in the left ventricle—a distinct clinical syndrome.
Circ Arrhythmia Electrophysiol 2008;1:23–9.
69. Yamada T, McElderry HT, Okada T, et al. Idiopathic focal ventric-
ular arrhythmias originating from the anterior papillary muscle in the
left ventricle. J Cardiovasc Electrophysiol 2009;20:866–72.
70. Daniels DV, Lu YY, Morton JB, et al. Idiopathic epicardial left
ventricular tachycardia originating remote from the sinus of Valsalva:
electrophysiologic characteristics, catheter ablation, and identification
from the 12-lead electrocardiogram. Circulation 2006;113:1659–66.
71. Schwartz PJ, Moss AJ, Vincent GM, et al. Diagnostic criteria for the
long QT syndrome. An update. Circulation 1993;88:782–4.
72. Priori SG, Napolitano C. Genetics of Channelopathies and Clinical
Implications. In: Fuster V, editor. Hurst’s The Heart. 13th edition.
New York, NY: McGraw Hill, 2011:897–910.
73. Splawski I, Shen J, Timothy KW, et al. Spectrum of mutations in
long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1,
and KCNE2. Circulation 2000;102:1178–85.
74. Lehnart SE, Ackerman MJ, Benson DW Jr., et al. Inherited
arrhythmias: a National Heart, Lung, and Blood Institute and Office
of Rare Diseases workshop consensus report about the diagnosis,
phenotyping, molecular mechanisms, and therapeutic approaches for
primary cardiomyopathies of gene mutations affecting ion channel
function. Circulation 2007;116:2325–45.
75. Tester DJ, Will ML, Haglund CM, et al. Effect of clinical phenotype
on yield of long QT syndrome genetic testing. J Am Coll Cardiol
2006;47:764–8.
76. Schwartz PJ, Priori SG, Spazzolini C, et al. Genotype-phenotype
correlation in the long-QT syndrome: gene-specific triggers for
life-threatening arrhythmias. Circulation 2001;103:89–95.
77. Zhang L, Timothy KW, Vincent GM, et al. Spectrum of ST-T–
wave patterns and repolarization parameters in congenital long-QT
syndrome: ECG findings identify genotypes. Circulation 2000;102:
2849–55.
78. Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the
long-QT syndrome. N Engl J Med 2003;348:1866–74.
79. Priori SG, Napolitano C, Schwartz PJ, et al. Association of long QT
syndrome loci and cardiac events among patients treated with
beta-blockers. JAMA 2004;292:1341–4.
80. Vincent GM, Schwartz PJ, Denjoy I, et al. High efficacy of
beta-blockers in long-QT syndrome type 1: contribution of noncom-
pliance and QT-prolonging drugs to the occurrence of beta-blocker
treatment “failures.” Circulation 2009;119:215–21.
81. Ruan Y, Liu N, Bloise R, et al. Gating properties of SCN5A
mutations and the response to mexiletine in long-QT syndrome type
3 patients. Circulation 2007;116:1137–44.82. Moss AJ, Windle JR, Hall WJ, et al. Safety and efficacy of flecainide
in subjects with long QT-3 syndrome (DeltaKPQ mutation): a
randomized, double-blind, placebo-controlled clinical trial. Ann
Noninvas Electrocardiol 2005;10 Suppl 4:59–66.
83. Moss AJ, Zareba W, Schwarz KQ, et al. Ranolazine shortens
repolarization in patients with sustained inward sodium current due
to type-3 long-QT syndrome. J Cardiovasc Electrophysiol 2008;19:
1289–93.
84. Schwartz PJ, Priori SG, Cerrone M, et al. Left cardiac sympathetic
denervation in the management of high-risk patients affected by the
long-QT syndrome. Circulation 2004;109:1826–33.
85. Haïssaguerre M, Extramiana F, Hocini M, et al. Mapping and
ablation of ventricular fibrillation associated with long-QT and
Brugada syndromes. Circulation 2003;108:925–8.
86. Brugada P, Brugada J. Right bundle branch block, persistent ST-
segment elevation and sudden cardiac death: a distinct clinical and
electrocardiographic syndrome. A multicenter report. J Am Coll
Cardiol 1992;20:1391–6.
87. Antzelevitch C, Brugada P, Borggrefe M, et al. Brugada syndrome:
report of the Second Consensus Conference. Circulation 2005;111:
659–70.
88. Nademanee K, Veerakul G, Nimmannit S, et al. Arrhythmogenic
marker for the sudden unexplained death syndrome in Thai men.
Circulation 1997;96:2595–600.
89. Bai R, Napolitano C, Bloise R. Yield of genetic screening in inherited
cardiac channelopathies: how to prioritize access to genetic testing.
Circ Arrhyth Electrophysiol 2009;2:6–15.
90. Bezzina C, Veldkamp MW, van Den Berg MP, et al. A single Na()
channel mutation causing both long-QT and Brugada syndromes.
Circ Res 1999;85:1206–13.
91. Grant AO, Carboni MP, Neplioueva V, et al. Long QT syndrome,
Brugada syndrome, and conduction system disease are linked to a
single sodium channel mutation. J Clin Invest 2002;110:1201–9.
92. Belhassen B, Glick A, Viskin S. Efficacy of quinidine in high-risk
patients with Brugada syndrome. Circulation 2004;110:1731–7.
93. Priori SG, Napolitano C, Gasparini M, et al. Natural history of
Brugada syndrome: insights for risk stratification and management.
Circulation 2002;105:1342–7.
94. Paul M, Gerss J, Schulze-Bahr E, et al. Role of programmed
ventricular stimulation in patients with Brugada syndrome: a meta-
analysis of worldwide published data. Eur Heart J 2007;28:2126–33.
95. Probst V, Veltmann C, Eckardt L, et al. Long-term prognosis of
patients diagnosed with Brugada syndrome: results from the
FINGER Brugada syndrome registry. Circulation 2010;121:635–43.
96. Morita H, Kusano KF, Miura D, et al. Fragmented QRS as a marker
of conduction abnormality and a predictor of prognosis of Brugada
syndrome. Circulation 2008;118:1697–704.
97. Hermida JS, Denjoy I, Clerc J, et al. Hydroquinidine therapy in
Brugada syndrome. J Am Coll Cardiol 2004;43:1853–60.
98. Mok NS, Chan NY, Chiu AC. Successful use of quinidine in
treatment of electrical storm in Brugada syndrome. Pacing Clin
Electrophysiol 2004;27:821–3.
99. Maury P, Couderc P, Delay M, et al. Electrical storm in Brugada
syndrome successfully treated using isoprenaline. Europace 2004;6:
130–3.
100. Nademanee K, Veerakul G, Chandanamattha P, et al. Prevention of
ventricular fibrillation episodes in Brugada syndrome by catheter
ablation over the anterior right ventricular outflow tract epicardium.
Circulation 2011;123:1270–9.
101. Priori SG, Napolitano C, Tiso N, et al. Mutations in the cardiac
ryanodine receptor gene (hRyR2) underlie catecholaminergic poly-
morphic ventricular tachycardia. Circulation 2001;103:196–200.
102. Lahat H, Eldar M, Levy-Nissenbaum E, et al. Autosomal recessive
catecholamine- or exercise-induced polymorphic ventricular tachy-
cardia: clinical features and assignment of the disease gene to
chromosome 1p13-21. Circulation 2001;103:2822–7.
103. Priori SG, Napolitano C, Memmi M, et al. Clinical and molecular
characterization of patients with catecholaminergic polymorphic
ventricular tachycardia. Circulation 2002;106:69–74.
104. Leenhardt A, Lucet V, Denjoy I, et al. Catecholaminergic polymor-
phic ventricular tachycardia in children. A 7-year follow-up of 21
patients. Circulation 1995;91:1512–9.
1744 Prystowsky et al. JACC Vol. 59, No. 20, 2012
Ventricular Arrhythmias in Normal Hearts May 15, 2012:1733–44105. Katz G, Arad M, Eldar M. Catecholaminergic polymorphic ventric-
ular tachycardia from bedside to bench and beyond. Curr Probl
Cardiol 2009;34:9–43.
106. Rosso R, Kalman JM, Rogowski O, et al. Calcium channel blockers
and beta-blockers versus beta-blockers alone for preventing exercise-
induced arrhythmias in catecholaminergic polymorphic ventricular
tachycardia. Heart Rhythm 2007;4:1149–54.
107. Watanabe H, Chopra N, Laver D, et al. Flecainide prevents
catecholaminergic polymorphic ventricular tachycardia in mice and
humans. Nat Med 2009;15:380–3.
108. Van der Werf C, Kannankeril PJ, Sacher F, et al. Flecainide therapy
reduces exercise-induced ventricular arrhythmias in patients with
catecholaminergic polymorphic ventricular tachycardia. J Am Coll
Cardiol 2011;57:2244–54.
109. Wilde AA, Bhuiyan ZA, Crotti L, et al. Left cardiac sympathetic
denervation for catecholaminergic polymorphic ventricular tachycar-
dia. N Engl J Med 2008;358:2024–9.
110. Gollob MH, Redpath CJ, Roberts JD. The short QT syndrome:
proposed diagnostic criteria. J Am Coll Cardiol 2011;57:802–12.
111. Bjerregaard P, Gussak I. Short QT syndrome: mechanisms, diagnosis
and treatment. Nat Clin Pract Cardiovasc Med 2005;2:84–7.
112. Wolpert C, Schimpf R, Giustetto C, et al. Further insights into the
effect of quinidine in short QT syndrome caused by a mutation in
HERG. J Cardiovasc Electrophysiol 2005;16:54–8.113. Haissaguerre M, Sacher F, Nogami A, et al. Characteristics of
recurrent ventricular fibrillation associated with inferolateral early
repolarization role of drug therapy. J Am Coll Cardiol 2009;53:612–9.
114. Knecht S, Sacher F, Wright N, et al. Long-term follow-up of
idiopathic ventricular fibrillation ablation. J Am Coll Cardiol 2009;
54:522–8.
115. Haissaguerre M, Derval N, Sacher F, et al. Sudden cardiac arrest
associated with early repolarization. N Engl J Med 2008;358:
2016 –23.
116. Benito B, Guasch E, Rivard L, Nattel S. Clinical and mechanistic
issues in early repolarization. J Am Coll Cardiol 2010;56:1177–86.
117. Haissaguerre M, Chatel S, Sacher F, et al. Ventricular fibrillation
with prominent early repolarization associated with a rare variant
of KCNJ8/KATP channel. J Cardiovasc Electrophysiol 2009;20:
93– 8.
118. Tikkanen JT, Junttila J, Anttonen O, et al. Early repolarization:
electrocardiographic phenotypes associated with favorable long-term
outcome. Circulation 2011;123:2666–73.
Key Words: implantable cardioverter-defibrillator y structural heart
disease y sudden cardiac death y ventricular fibrillation y ventricular
tachycardia.
